Infant Clinical Nutrition Market

Infant Clinical Nutrition Market Outlook (2024 to 2034)

Revenue from the global infant clinical nutrition market is estimated to reach US$ 27.55 billion in 2024. The market is analyzed to rise at a CAGR of 6% to reach US$ 49.47 billion by the end of 2034.

The industry is devoted to producing, distributing, and selling nutritional supplements specially made for infants-including premature babies or those with certain medical conditions-is known as infant clinical nutrition. These goods are necessary to guarantee healthy development, growth, and general well-being in the early years of life. The market includes a wide range of goods, including baby formula, dietary supplements, and customized formulations for babies with allergies, digestive problems, or other medical conditions.

Key Market Growth Drivers

• Global demand for premium infant nutrition food products is rising as a result of growing knowledge of the nutritional needs of newborns. The growing urbanization and globalization trends, together with the busier lifestyle that consumers everywhere are leading, are driving infant clinical nutrition market growth.
• The growing birth rate in potentially high-growth countries worldwide is contributing to an increase in the global population. Several wealthy countries are attempting to increase the birth rate through government initiatives. Simultaneously, the global rate of premature newborns has peaked in the last several years.
• Over 15 million preterm births are estimated to occur each year, according to the World Health Organization (WHO). One of the main reasons for child death is problems from preterm birth, which is severe enough to prove lethal. Worldwide, there is a growing need for efficient, nutrient-rich supplements to increase the survival rate of premature infants. The world's leading governments and organizations are working to improve the outcomes of preterm deliveries, thereby there is a growing need for infant clinical nutrition, which is estimated to increase in the years to come.
• The need for nutrient-dense supplements for infants is rising as working mothers give birth to children worldwide. Rising household incomes and heightened knowledge of the essentials of newborn health have made consumers willing to shell out more money for superior or premium nutrition items for their infants.
• Several manufacturers across the globe are producing newborn clinical nutrition products due to the ongoing progress in biotechnology and the growing purchasing power of customers.
• Wide ranges of substances are used by manufacturers to improve metabolic results. It is now feasible for market participants to achieve long-term developmental outputs of infant clinical nutritional products thanks to cutting-edge research on neonatal care. In the next years, highly sophisticated and effective products are projected to be introduced into the global infant clinical nutrition market.
• Several kinds of advanced clinical nutrition products for newborns are widely available in the global market. These products include milk-based, soy-based, probiotic/prebiotic, and organic goods, thus increasing infant clinical nutrition market size.

Report Attributes	Details
Infant Clinical Nutrition Market Size (2024E)	US$ 27.55 Billion
Forecasted Market Value (2034F)	US$ 49.47 Billion
Global Market Growth Rate (2024 to 2034)	6% CAGR
East Asia Market Share (2024E)	22.4%
North America Growth Rate (2024 to 2034)	6.2% CAGR
Demand for Organic Products (2024E)	US$ 7.6 Billion
Key Companies Profiled	Abbott Laboratories; Baxter International Inc.; Nestlé S.A.; Danone; Meiji Holdings Co., Ltd.; Fresenius SE & Co. KGaA; Reckitt Benckiser Group Plc; Perrigo Co. Plc; Ingredion Inc.; Solace Nutrition

What are the Key Drivers that are Influencing the Market for Infant Clinical Nutrition?

“Preterm Births and Rising Infant Mortality Rates Driving Need for Baby Therapeutic Nutrition”

The market for specialist infant nutrition products is driven by growing knowledge of the significance of a healthy diet throughout infancy. The advantages of clinical nutrition for the development and growth of their children are better understood by parents. The need for infant clinical nutrition is increasing due to preterm births and rising infant mortality rates in some areas, especially for products meant to sustain underweight and preterm newborns.

Wide ranges of substances are used by manufacturers to improve metabolic results. It is now feasible for market participants to achieve long-term developmental outputs of infant clinical nutritional products due to cutting-edge research on neonatal care. In the next years, highly sophisticated and effective products are anticipated to be introduced into the global market. Several kinds of advanced clinical nutrition products for newborns are widely available in the global market. These products include milk-based, soy-based, probiotic/prebiotic, and organic goods.

What are the Challenges Faced by Manufactures of Infant Clinical Nutrition?

“Standards for Baby Food Labeling and Nutrient Requirements by Regulations Governing Newborn Clinical Nutrition”

The majority of governments across the world are putting strict regulations and requirements on producers and distributors to guarantee the effectiveness and quality of newborn clinical nutrition products. Global regulatory agencies, such as the European Food Safety Authority (EFSA), the Canadian Food Inspection Agency, and the U.S. Food and Drug Administration (FDA), have established stringent guidelines that manufacturers must adhere to. Regulations governing infant clinical nutrition products are providing nutrient requirements and labeling standards for baby food. Prolonged approval procedures are shown by the requirement for manufacturers to submit the product specifications at least ninety days before their products are marketed in the United States.

Country-wise Insights

The market in East Asia is analyzed to hold 22.4% of the global infant clinical nutrition market share in 2024. Meanwhile, North America is estimated to hold a market share of 23.9% in 2024. The increase in the purchasing power of the population in the Asia-Pacific area has significantly increased the demand for newborn nutrition products. In addition, the government has started initiatives to promote baby care. Additionally, a rise in online marketing for wholesome and nutritious newborn food would support the growth of the infant nutrition sector. Additionally, businesses that have been founded in this area are also focusing on releasing innovative products based on local demand.

What is Driving the Market for Infant Clinical Nutrition in the United States?

“Since More Newborns Are Being Born with Food Allergies or Intolerances, Growing Need for Hypoallergenic and Specialist Infant Nutrition Formulas”

Attribute	United States
Market Value (2024E)	US$ 2.93 Billion
Growth Rate (2024 to 2034)	6.5% CAGR
Projected Value (2034F)	US$ 5.48 Billion

The demand for newborn clinical nutrition products is mostly driven by the rise in working mothers in the United States. There is a higher reliance on infant formula and other nutritional solutions, especially those that can replace breast milk, as breastfeeding is not always practical for many working parents. The country has one of the highest rates of preterm deliveries. The need for goods catered to the demands of this demographic is fueled by the fact that prematurely born infants frequently need specialized clinical nutrition to maintain their growth. The need for hypoallergenic and specialty infant nutrition formulae is rising as more babies are born with food allergies or intolerances, such as lactose intolerance or cow's milk protein allergy. This is especially true for goods that contain components such as amino acids or hydrolyzed proteins.

What is the Sales Outlook for Infant Clinical Nutrition in China?

“Growing Preference for Dietary Goods Clinically Proven and Specialized”

Attribute	China
Market Value (2024E)	US$ 3.02 Billion
Growth Rate (2024 to 2034)	6% CAGR
Projected Value (2034F)	US$ 5.43 Billion

A new wave of cutting-edge, scientifically developed nutrition items is hitting the market in China. Human milk oligosaccharides (HMOs), probiotics, and DHA-enriched formulas are among the innovations that manufacturers are launching. These advancements are becoming popular among health-conscious parents who want to give their babies the finest nutrition possible. A part of the reason for the growing awareness of the significance of newborn nutrition among people in China is the easier access to information provided by social media and the internet. There is an increasing preference for clinically established and specialized nutrition products among parents who are aware of the long-term health benefits of appropriate nutrition during infancy.

The emergence of cross-border sales channels and rising e-Commerce platforms in China has facilitated parents' access to premium foreign baby feeding brands. The demand for imported newborn clinical nutrition products has increased because of cross-border e-Commerce, particularly from countries like Australia and Europe that have strict food safety regulations and quality control systems in place.

Category-wise Insights

The market for infant clinical nutrition is categorized into oral administration, enteral administration, and intravenous administration by route of administration. The intravenous segment is estimated to capture more than half of the market share in 2024. In terms of product type, the market is segmented into milk, soy, organic, and probiotic/prebiotic segments, out of which the organic segment is forecasted to hold a significant share of 27.6% in 2024.

By Route of Administration Which Segment is Responsible for a Significant Share of Infant Clinical Nutrition?

“Growing Requirements for Parenteral Nutrition among Infants with Severe Congenital GI Tract Anomalies“

Attribute	Intravenous Administration
Segment Value (2024E)	US$ 14.87 Billion
Growth Rate (2024 to 2034)	6% CAGR
Projected Value (2034F)	US$ 26.57 Billion

Parenteral nutrition (PN), also referred to, as intravenous (IV) administration for baby clinical nutrition, is a medical strategy utilized when a newborn's digestive system is unable to provide enough nutrients. Bypassing the digestive system, this technique uses an IV line to give vital nutrients straight into the bloodstream. IV nourishment is required for extremely preterm infants since their digestive systems are frequently undeveloped and unable to handle oral or enteral feeding. Parenteral nourishment necessary for infants suffering from severe congenital abnormalities of the GI tract, necrotizing enterocolitis (NEC), or small bowel syndrome. Infants undergoing digestive system-related procedures could IV nourishment until their digestive system functions well. Severe malabsorption syndromes cause newborns to have impaired gastrointestinal absorption of nutrients.

Which Product Type is Mostly Used as Infant Clinical Nutrition?

“Absence of Natural Fertilizers and Artificial Chemicals in Farming of Ingredients Used in Organic Baby Food Products”

Attribute	Organic
Segment Value (2024E)	US$ 7.6 Billion
Growth Rate (2024 to 2034)	6% CAGR
Projected Value (2034F)	US$ 13.65 Billion

Ingredients for organic baby food items are farmed without the use of artificial chemicals, fertilizers, or genetically modified organisms. Regulation authorities such as the United States Department of Agriculture (USDA) or the European Union Organic Certification establish standards for organic certification, which these items must meet. Artificial coloring, flavorings, sweeteners, and preservatives are not included in organic clinical nutrition for infants. For infants with fragile digestive systems or allergies, this is especially crucial.

Competition Analysis

Key players in the infant clinical nutrition industry have significant financial resources that are invested in the development of new technologies to enhance production efficiency and optimize supply chains in response to a gradual increase in demand. Investing money in the branding and advertising of their items is aiding in drawing in new clients and strengthening those that already exist.

• To support newborns' development throughout their life stages, Nestlé unveiled a new commercial blend of infant nutrition called Sinergity in October 2023. This combination includes a probiotic strain with varying stages of six human milk oligosaccharides (HMOs).
• To satisfy consumer expectations for feeding solutions that are appropriate for vegetarian, flexitarian, and plant-based diets as well as meet their baby's unique nutritional needs, Danone S.A. introduced the new dairy & plant mix baby formula in July 2022.
• The manufacturer of baby formula announced in February 2022 regarding the launch of Arla Foods Amba's milk fractionation technology, called ORIGIN.
• Abbott Laboratories introduced Similac 360 Total Care, an infant formula containing a combination of five distinct human milk oligosaccharides, in November 2021. This novel formula offers nourishment to support the growth and wellness of the baby's entire body, including the growing brain, digestive system, and immune system.

Fact.MR provides detailed information about the price points of the leading providers in the infant clinical nutrition market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Infant Clinical Nutrition Market Research

• By Route of Administration :

  • Oral Administration
  • Enteral Administration
  • Intravenous Administration

• By Product Type :

  • Milk-Based
  • Soy-Based
  • Organic
  • Probiotic/Prebiotic

• By Region :

  • North America
  • Europe
  • East Asia
  • Latin America
  • South Asia & Pacific
  • Eastern Europe
  • Middle East & Africa